Analysis of fecal metabolomics in patients with inflammatory bowel disease through mass spectrometry
inflammatory bowel disease; Crohn's disease; ulcerative colitis; ulcerative colitis; omics; metabolomics; fecal metabolites; calprotectin; inflammatory bowel markers.
Inflammatory Bowel Disease (IBD) is divided into Crohn's disease (CD) and Ulcerative Colitis (UC), and refers to an inflammatory pathology of chronic and idiopathic character, where there is a possible dysregulation of homeotase between the intestinal immune system and the microbiota in genetically susceptible individuals. Patients with IDI have significant differences in fecal metabolomics compared to healthy people. Metabolomics is the analysis of these metabolites that can relate to certain pathologies, including intestinal ones. The study aims to analyze the intestinal metabolic profile of patients with Inflammatory Bowel Disease followed by a specialized service in a reference hospital in Maceió/AL, using mass spectrometry. We selected 62 patients with inflammatory bowel disease who were submitted to a questionnaire for clinical evaluation, and a fecal sample was collected for analysis of metabolomics and fecal calprotectin. The control group is composed of 30 fecal samples of healthy individuals according to the inclusion criteria for the analysis of metabolites. Metabolomic data were analyzed using MetaboAnalyst 5.0 Software.